Hexaell Biotech advances liver program with $31 million raise
Shanghai-based biotech firm Hexaell Biotech has secured 200 million renminbi ($31 million) in a series B+ funding round. The investment was led by Shanghai Biomedical Fund, with continued support from existing backer Longpan Investment and participation from Guanghua Wutong.
The funds will accelerate clinical research and commercial production of the company's flagship product, HepaCure, and advance its pipeline of liver disease candidates.
Established in 2015, the firm focuses on cell therapy and regenerative medicine for liver diseases. Its core technology enables direct conversion of somatic cells into hepatocyte-like cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze